• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    TransMedics Reports Second Quarter 2025 Financial Results

    7/30/25 4:05:00 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $TMDX alert in real time by email

    ANDOVER, Mass., July 30, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2025.

    (PRNewsfoto/TransMedics, Inc.)

    Recent Highlights

    • Total revenue of $157.4 million in the second quarter of 2025, a 38% increase compared to the second quarter of 2024
    • Generated net income of $34.9 million or $0.92 per fully diluted share in the second quarter of 2025
    • Received conditional Investigations Device Exemption (IDE) approval from the U.S. Food and Drug Administration to initiate the Next-Gen OCS™ Lung trial
    • Launched first-in-class OCS NOP digital ecosystem, NOP ACCESS™, across major NOP™ transplant programs across the U.S.
    • Raising full year 2025 revenue guidance to $585 million to $605 million

    "We are proud to report another strong quarter, marked by profitable year-over-year revenue growth of 38%. Our consistent performance across all areas of the business reflects the successful execution of our strategy, the differentiated value our OCS and NOP platforms, and our unique leadership position in the transplant market," said Waleed Hassanein, MD, President and Chief Executive Officer. "Looking ahead, we are confident in our strategy and remain laser focused on achieving and surpassing the target of 10,000 US NOP transplants in 2028, while ramping up investments to drive the next several waves of growth aimed at delivering significant top-and bottom-line growth for our business."

    Second Quarter 2025 Financial Results

    Total revenue for the second quarter of 2025 was $157.4 million, a 38% increase compared to $114.3 million in the second quarter of 2024. The increase was due primarily to the increase in utilization of the Organ Care System ("OCS"), primarily in Liver and Heart through the National OCS Program ("NOP") and related NOP service revenue fueled by the continued expansion and utilization of our aviation fleet.

    Gross margin for the second quarter of 2025 was 61% consistent with the second quarter of 2024.

    Operating expenses for the second quarter of 2025 were $60.0 million, compared to $56.8 million in the second quarter of 2024. The increase in operating expenses was driven primarily by increased research and development investment as well as investment throughout the organization to support the growth of the company. Second quarter operating expenses in 2025 included $9.0 million of stock compensation expense compared to $7.3 million of stock compensation expense in the second quarter of 2024.

    Net income for the second quarter of 2025 was $34.9 million, 22% of revenue, compared to net income of $12.2 million in the second quarter of 2024.

    Cash was $400.6 million as of June 30, 2025.

    2025 Financial Outlook

    TransMedics is raising its full year 2025 revenue guidance to be in the range of $585 million to $605 million, which represents 35% growth at the midpoint compared to the company's prior year revenue. TransMedics' full year 2025 revenue guidance as reported on May 8, 2025 was previously in the range of $565 million to $585 million.

    Webcast and Conference Call Details

    The TransMedics management team will host a conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT on Thursday, July 30, 2025. Investors interested in listening to the conference call may do so by dialing (844) 676-6010 for domestic callers or (412) 634-6944 for international callers and ask to be joined into the TransMedics call. A live and archived webcast of the event and the company's slide presentation with information on second quarter 2025 financial results will be available on the "Investors" section of the TransMedics website at www.transmedics.com.

    About TransMedics Group, Inc.

    TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

    Forward-Looking Statements

    This press release contains forward-looking statements. These forward-looking statements address various matters, including, among other things, future results and events, including financial guidance and projected estimates, and statements about our strategy, our focus on achieving and surpassing the target of 10,000 US NOP transplants in 2028, investments to drive waves of growth, and financial and business growth. For this purpose, all statements other than statements of historical facts are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "could," "target," "predict," "seek" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties. Our management cannot predict all risks, nor can we assess the impact of all factors or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated in or implied by the forward-looking statements. Some of the key factors that could cause actual results to differ include: the fluctuation of our financial results from quarter to quarter; our ability to attract, train, and retain key personnel; our existing and any future indebtedness, including our ability to comply with affirmative and negative covenants under our credit agreements to which we will remain subject until maturity; our ability to sustain profitability; our need to raise additional funding and our ability to obtain it on favorable terms, or at all; our ability to use net operating losses and research and development credit carryforwards; that we have identified a material weakness in our internal control over financial reporting, and that we may identify additional material weaknesses in the future; our dependence on the success of the Organ Care System ("OCS"); our ability to expand access to the OCS through our National OCS Program ("NOP"); our ability to improve the OCS platform, including by developing the next generation of the OCS products or expanding into new indications; our ability to scale our manufacturing and sterilization capabilities to meet increasing demand for our products; the rate and degree of market acceptance of the OCS; our ability to educate patients, surgeons, transplant centers and private and public payors of benefits offered by the OCS; our dependence on a limited number of customers for a significant portion of our revenue; our ability to maintain regulatory approvals or clearances for our OCS products in the United States, the European Union, and other select jurisdictions worldwide; our ability to adequately respond to Food and Drug Administration ("FDA"), or other competent authorities, follow-up inquiries in a timely manner; the impact of healthcare policy changes, including recently enacted or potential future legislation reforming the U.S. healthcare system or the FDA; the performance of our third-party suppliers and manufacturers; our use of third parties to transport donor organs and medical personnel for our NOP and our ability to maintain and grow our logistics capabilities to support our NOP to reduce dependence on third party transportation, including by means of attracting, training and retaining pilots, and the acquisition, maintenance or replacement of fixed-wing aircraft for our aviation transportation services or other acquisitions, joint ventures or strategic investments; our ability to maintain Federal Aviation Administration ("FAA") or other regulatory licenses or approvals for our aircraft transportation services; price increases of the components of our products and maintenance, parts and fuel for our aircraft; the timing or results of post-approval studies and any clinical trials for the OCS; our manufacturing, sales, marketing and clinical support capabilities and strategy; attacks against our information technology infrastructure; the economic, political and other risks associated with our foreign operations; our ability to protect, defend, maintain and enforce our intellectual property rights relating to the OCS and avoid allegations that our products or services infringe, misappropriate or otherwise violate the intellectual property rights of third parties; the pricing of the OCS, as well as the reimbursement coverage for the OCS in the United States and internationally; regulatory developments in the United States, European Union and other jurisdictions; the extent and success of competing products or procedures that are or may become available; our ability to service our 1.50% convertible senior notes, due 2028; the impact of any product recalls or improper use of our products; our estimates regarding revenues, expenses and needs for additional financing; and other factors that may be described in our filings with the Securities and Exchange Commission (the "SEC"). Additional information will be made available in our annual and quarterly reports and other filings that we make with the SEC. The forward-looking statements in this press release speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and we are not able to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

    Investor Contact:

    Brian Johnston

    Laine Morgan

    332-895-3222

    [email protected]

    TransMedics Group, Inc.

    CONSOLIDATED STATEMENTS OF OPERATIONS

    (in thousands, except share and per share data)

    (unaudited)







    Three Months Ended June 30,



    Six Months Ended June 30,





    2025



    2024



    2025



    2024

    Revenue:

















    Net product revenue



    $                     96,100



    $                     71,732



    $                   184,334



    $                   133,057

    Service revenue



    61,270



    42,573



    116,573



    78,098

    Total revenue



    157,370



    114,305



    300,907



    211,155

    Cost of revenue:

















    Cost of net product revenue



    19,421



    14,470



    35,733



    28,554

    Cost of service revenue



    41,360



    30,574



    80,357



    53,378

    Total cost of revenue



    60,781



    45,044



    116,090



    81,932

    Gross profit



    96,589



    69,261



    184,817



    129,223



















    Gross margin



    61 %



    61 %



    61 %



    61 %



















    Operating expenses:

















    Research, development and clinical trials



    15,934



    13,858



    33,094



    25,238

    Selling, general and administrative



    44,088



    42,895



    87,713



    79,056

    Total operating expenses



    60,022



    56,753



    120,807



    104,294

    Income from operations



    36,567



    12,508



    64,010



    24,929

    Other income (expense):

















    Interest expense



    (3,476)



    (3,623)



    (6,937)



    (7,221)

    Interest income and other income (expense), net



    3,091



    3,268



    5,785



    6,838

    Total other expense, net



    (385)



    (355)



    (1,152)



    (383)

    Income before income taxes



    36,182



    12,153



    62,858



    24,546

    (Provision) benefit for income taxes



    (1,275)



    41



    (2,269)



    (155)

    Net income



    $                     34,907



    $                     12,194



    $                     60,589



    $                     24,391

    Net income per share:

















    Basic



    $                         1.03



    $                         0.37



    $                         1.79



    $                         0.74

    Diluted



    $                         0.92



    $                         0.35



    $                         1.62



    $                         0.70

    Weighted average common shares outstanding:

















    Basic



    33,912,669



    33,119,514



    33,817,664



    32,939,852

    Diluted



    40,558,953



    35,288,308



    40,238,501



    34,983,603

     

    TransMedics Group, Inc.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in thousands)

    (unaudited)









    June 30, 2025



    December 31, 2024

    Assets









    Current assets:









    Cash



    $                   400,575



    $                   336,650

    Accounts receivable



    104,851



    97,722

    Inventory



    38,868



    46,554

    Prepaid expenses and other current assets



    13,835



    16,290

               Total current assets



    558,129



    497,216

    Property, plant and equipment, net



    312,255



    285,970

    Operating lease right-of-use assets



    5,818



    6,481

    Restricted cash



    500



    500

    Goodwill



    11,549



    11,549

    Acquired intangible assets, net



    2,050



    2,152

    Other non-current assets



    221



    208

               Total assets



    $                   890,522



    $                   804,076

    Liabilities and Stockholders' Equity









    Current liabilities:









    Accounts payable



    $                       9,539



    $                     10,292

    Accrued expenses and other current liabilities



    42,490



    45,152

    Deferred revenue



    1,570



    1,742

    Operating lease liabilities



    3,021



    2,727

    Total current liabilities



    56,620



    59,913

    Convertible senior notes, net



    451,364



    449,939

    Long-term debt, net



    59,525



    59,372

    Operating lease liabilities, net of current portion



    4,912



    6,249

        Total liabilities



    572,421



    575,473

        Total stockholders' equity



    318,101



    228,603

        Total liabilities and stockholders' equity



    $                   890,522



    $                   804,076

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-reports-second-quarter-2025-financial-results-302517787.html

    SOURCE TransMedics Group, Inc.

    Get the next $TMDX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TMDX

    DatePrice TargetRatingAnalyst
    12/17/2024$116.00 → $75.00Overweight → Neutral
    Analyst
    11/22/2024Buy → Hold
    Needham
    10/29/2024$200.00 → $125.00Outperform
    Oppenheimer
    10/29/2024$208.00 → $109.00Buy
    Needham
    9/24/2024$200.00Outperform
    Robert W. Baird
    8/21/2024$208.00Buy
    Needham
    6/6/2024$161.00Overweight
    Cantor Fitzgerald
    6/4/2024$151.00Overweight
    Stephens
    More analyst ratings

    $TMDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TransMedics Reports Second Quarter 2025 Financial Results

      ANDOVER, Mass., July 30, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2025. Recent Highlights Total revenue of $157.4 million in the second quarter of 2025, a 38% increase compared to the second quarter of 2024Generated net income of $34.9 million or $0.92 per fully diluted share in the second quarter of 2025Received conditional Investigations Device

      7/30/25 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • TransMedics to Present at the Canaccord Genuity 45th Annual Growth Conference

      ANDOVER, Mass., July 29, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming Canaccord Genuity 45th Annual Growth Conference at the InterContinental Boston Hotel. Management is scheduled to present on Tuesday, August 12, 2025, at 11:30 a.m. Eastern Standard Time. Event: Canaccord Genuity 45th Annual Growth ConferenceDate: Tuesday, August 12,

      7/29/25 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • TransMedics to Report Second Quarter 2025 Financial Results on July 30, 2025

      ANDOVER, Mass., July 16, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2025 after market close on Wednesday, July 30, 2025. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (844) 676-6010 for dome

      7/16/25 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TMDX
    SEC Filings

    See more
    • SEC Form 10-Q filed by TransMedics Group Inc.

      10-Q - TransMedics Group, Inc. (0001756262) (Filer)

      7/30/25 4:29:15 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • TransMedics Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - TransMedics Group, Inc. (0001756262) (Filer)

      7/30/25 4:09:24 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SD filed by TransMedics Group Inc.

      SD - TransMedics Group, Inc. (0001756262) (Filer)

      5/30/25 4:15:33 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TMDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TransMedics Group downgraded by Analyst with a new price target

      Analyst downgraded TransMedics Group from Overweight to Neutral and set a new price target of $75.00 from $116.00 previously

      12/17/24 8:22:54 AM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • TransMedics Group downgraded by Needham

      Needham downgraded TransMedics Group from Buy to Hold

      11/22/24 8:05:47 AM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Oppenheimer reiterated coverage on TransMedics Group with a new price target

      Oppenheimer reiterated coverage of TransMedics Group with a rating of Outperform and set a new price target of $125.00 from $200.00 previously

      10/29/24 7:47:16 AM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TMDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Ranganath Anil P. sold $95,903 worth of shares (686 units at $139.80), decreasing direct ownership by 5% to 13,955 units (SEC Form 4)

      4 - TransMedics Group, Inc. (0001756262) (Issuer)

      6/10/25 4:44:58 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Basile Edward M exercised 5,000 shares at a strike of $0.70 and sold $632,250 worth of shares (5,000 units at $126.45) (SEC Form 4)

      4 - TransMedics Group, Inc. (0001756262) (Issuer)

      5/29/25 4:30:11 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Basile Edward M was granted 2,134 shares, increasing direct ownership by 292% to 2,866 units (SEC Form 4)

      4 - TransMedics Group, Inc. (0001756262) (Issuer)

      5/23/25 6:48:25 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TMDX
    Financials

    Live finance-specific insights

    See more
    • TransMedics Reports Second Quarter 2025 Financial Results

      ANDOVER, Mass., July 30, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2025. Recent Highlights Total revenue of $157.4 million in the second quarter of 2025, a 38% increase compared to the second quarter of 2024Generated net income of $34.9 million or $0.92 per fully diluted share in the second quarter of 2025Received conditional Investigations Device

      7/30/25 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • TransMedics to Report Second Quarter 2025 Financial Results on July 30, 2025

      ANDOVER, Mass., July 16, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2025 after market close on Wednesday, July 30, 2025. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (844) 676-6010 for dome

      7/16/25 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • TransMedics Reports First Quarter 2025 Financial Results

      ANDOVER, Mass., May 8, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2025. Recent Highlights Total revenue of $143.5 million in the first quarter of 2025, a 48% increase compared to the first quarter of 2024Generated net income of $25.7 million or $0.70 per fully diluted share in the first quarter of 2025Raising full year 2025 revenue guidance to $565

      5/8/25 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TMDX
    Leadership Updates

    Live Leadership Updates

    See more
    • TransMedics Appoints Gerardo Hernandez as Chief Financial Officer and Provides Updated 2024 Financial Outlook

      ANDOVER, Mass., Dec. 2, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr. Gerardo Hernandez as the Company's Chief Financial Officer, effective December 2, 2024. In this role, Mr. Hernandez joins the TransMedics executive leadership team, succeeding Mr. Stephen Gordon. To enable a smooth transition, Mr. Gordon will remain a non-executive employee of the Company until March 31, 2025, before serving as a non-employee senior advisor to the Company focusing on national transplant stakeholder engagem

      12/2/24 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • The Ensign Group Set to Join S&P MidCap 400; Curbline Properties & TransMedics Group to Join S&P SmallCap 600

      NEW YORK, Sept. 26, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 and S&P MidCap 400: S&P SmallCap 600 constituent The Ensign Group Inc. (NASD: ENSG) will replace Southwestern Energy Co. (NYSE:SWN) in the S&P MidCap 400 and TransMedics Group, Inc. (NASD: TMDX) will replace The Ensign Group in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, October 1.  S&P MidCap 400 constituent Chesapeake Energy Corp. (NASD: CHK) is acquiring Southwestern Energy in a deal expected to be completed October 1.Curbline Properties Corp. (NYSE:CURB) will be added to the S&P SmallCap 600 effective prior to the open of trading on Tuesda

      9/26/24 6:04:00 PM ET
      $CCRN
      $CHK
      $ENSG
      $SITC
      Professional Services
      Consumer Discretionary
      Oil & Gas Production
      Energy
    • TransMedics Appoints Anil Ranganath as Senior Vice President, General Counsel and Corporate Secretary

      ANDOVER, Mass., July 26, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Anil Ranganath as Senior Vice President, General Counsel and Corporate Secretary. "We are excited to welcome Anil to the TransMedics leadership team," said Waleed Hassanein, MD, President and Chief Executive Officer. "Anil brings a wealth of healthcare industry experience, and his knowledge and counsel will be

      7/26/23 5:09:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TMDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by TransMedics Group Inc.

      SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)

      10/7/24 11:37:08 AM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by TransMedics Group Inc.

      SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)

      10/4/24 4:23:23 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by TransMedics Group Inc. (Amendment)

      SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)

      2/14/24 6:28:57 AM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care